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Opioid-induced hyperalgesia
as a problem in pain management.
Mechanisms of onset, diagnosis
and treatment
Abstract
Opioids have been used for centuries to control pain. One of the problems with their use is the development
of tolerance in some patients. This problem is usually solved by an increase in the dose. However, this does
not solve all the difficulties encountered. In some patients, the opioid doses needs rise very quickly. It seems
that this phenomenon depends on changes in the opioid receptors and on the organization of the functions
of the central nervous system. This phenomenon is known as opioid-induced hyperalgesia. Changes may
include the facilitation of pain conveyance which may more or less counteract the analgesic effect of the
same drug. Until now, several putative mechanisms have been identified. Here we shall explore the changes
of opioid receptors and changes in the glutaminergic system. In addition, the spinal cord and probably also
the liver are producing a specific peptide, Dynorphin A, which has an excitatory effect. The organization and
function of the On-Off cells in the brain are also changed. In this article, we discuss strategies for the
treatment of opioid-induced hyperalgesia. These strategies have the potential to improve the quality of
opioid analgesia.
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Introduction
Opioids have been used for pain control for cen-
turies. The analgesic effects of these drugs, howev-
er, is compromised by several negative (read neu-
roexcitatory) phenomena. These phenomena not in-
frequently complicate treatment and sometimes ex-
plain poor pain control and reluctance in opioids
being prescribed. We are talking here about toler-
ance and addiction to opioids. Opioid-naive patients
usually experience considerable decrease of pain sen-
sations. This effect correlates strongly with the pres-
ence of opioid receptors and the plasma levels of
the drugs and their metabolites. The analgesic ef-
fect also has a positive correlation to the dose of the
drug administered. Immediately after the first ad-
ministration of the drug, the central nervous system
starts to adapt to it. This adaptation may imply that
the patient is tolerant to opioids and higher doses
of the drug will be needed to achieve the same
pharmacological effects. Until now it was thought
that tolerance to opioids was mainly related to the
changes in opioid receptors. New drugs were in-
vented with a stronger and more specific effect on
opioid receptors. However, this approach certainly
did not solve problems of tolerance. On the con-
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trary, the more potent opioid drugs seemed to in-
duce tolerance more quickly and, as it now appears,
are prone to inducing more pain. This phenomenon
was called paradoxical pain in the past but only
recently was this changed to opioid-induced hyper-
algesia. This phenomenon can best be characterized
by the lowering of the pain threshold. Hyperalgesia
as such is encountered in many clinical situations.
Here we shall focus on hyperalgesia induced by opi-
oids. This phenomenon was suspected for a long
time, as it was known that patients addicted to
opioids present with a lower pain threshold and
higher sensitivity to pain [1]. One of the strongest
and most promising opioids, remifentanyl, ap-
peared to induce potent analgesia during its use
but after its discontinuation might induce even
more pain which results in higher consumption of
other opioids. [2, 3]. Thus it seems plausible that in
spite of antinociceptive effects, opioids may also
have a pro-nociceptive effect. This effect may form
a background for the development of addiction, as
each trial of the discontinuation of opioids results
in more pain and the immediate recommencement
of opioids administration.
In this article we shall focus on explanations of
the mechanism of hyperalgesia and the significance
of this phenomenon in the clinic. We shall also clar-
ify how to recognize this phenomenon in clinical
practice and also indicate how to prevent it.
Data from animal models
Analgesics were, for many years, tested using
the tail-flick test in rats. This test is sensitive in de-
tecting the potency of the drug but is totally insen-
sitive to the detection of a lowered pain threshold.
This is also the reason why many new potent opio-
ids were developed without any idea about the pain
threshold lowering capacity. Another procedure uti-
lizing the slow-rising stimulation curve, such as the
paw withdrawal test [4], is able to detect a lowering
of the pain threshold, however. Using this test, it
was shown that the 7-day-long administration of
morphine to rats causes a progressive lowering of
the pain threshold. Similar results were obtained
after the subcutaneous administration of fentanyl
[5, 6]. In these studies, it was shown that the lower-
ing of the pain threshold persisted for at least five
days after discontinuation of the drug. These data
were also replicated for diacetylmorphine [7]. Opio-
id analgesics, therefore, produce not only anti-noci-
ception but also pro-nociception which can be mea-
sured as a lowering of the pain threshold.
Clinical data
The pro-nociceptive effects of opioids had been
suspected for a long time but it was difficult to
show unequivocally [1]. The studies with remifenta-
nyl were decisive, where lowering of the pain thresh-
old was shown [8]. However, Cortez et al [9], in very
similar circumstances, found something completely
opposite. The studies with addicted subjects were
very interesting [10]. In these patients, the lowered
pain threshold following the prolonged use of opio-
ids appears to have been detected even many years
after the cure of addiction. Everybody who occa-
sionally treats pain in terminally ill, former addicts,
will know that the pain treatment in those subjects
is much more difficult. In cancer patients, there is
probably an additional hyperalgesia due to the tu-
mour itself [11]. Lowering of the pain threshold was
until now always interpreted as tumour progression




Until now, mechanisms contributing to the de-
velopment of hyperalgesia were divided into two
groups: one group contains those mechanisms re-
sponsible for desensitization (development of phar-
macological tolerance at the level of the opioid re-
ceptors); the second is characterized by sensitiza-
tion to pro-nociceptive effects (this can be mea-
sured as a lowering of the pain threshold). This lat-
ter group plays a role at the level of organization of
the whole central nervous system, not only its opio-
ids component. It is unknown how these mecha-
nisms can be clinically differentiated from each oth-
er and it is probable that both types of mechanism
may operate in the same subject and at the same
time.
Desensitization of opioid receptors
One of the most exciting hypotheses was pro-
posed and corroborated by Crain and Shen [12, 13].
According to these authors, peptide parts of opioid
receptors are coupled to Gi/Go proteins [12]. These
protein complexes are of an inhibitory nature. Inter-
action of this complex with an opioid will induce
inhibitory effects such as the inhibition of pain con-
veyance, depression of the respiratory centre, inhi-
bition of saliva production, constipation, and also
somnolence. Even after the first dose of opioids (in
www.advpm.eu 39
Zbigniew Zylicz, Ma‡gorzata Krajnik Opioid-induced hyperalgesia
opioid-naive patients) the synthesis of GM1 gangli-
oside increases in the neural tissues. This protein
causes uncoupling of the receptor peptides and cou-
pling with another, Gs protein. These complexes are
of an excitatory nature and after their stimulation
with opioid agonist they will cause hyperalgesia, an
increase in the respiratory rate, confusion and delir-
ium. For unknown reasons, increase in salivary pro-
duction and diarrhoea are not observed.
A change in at least some of the receptors from
inhibitory to excitatory mode can not only explain
phenomena such as opioid tolerance but also toler-
ance to respiratory depression due to opioids. Pa-
tients who receive opioids for a long time, respirato-
ry depression after an increase of the opioids dose is
only rarely seen.
Many doctors think that an increase of the opio-
id dose will not only improve the analgesic effect
but also induce somnolence or even sedation (ethi-
cal issues concerning this are out of the scope of
this paper). In fact, in many patients an increase of
the opioids dose, instead of causing somnolence
(inhibitory effect), will induce confusion and deliri-
um (excitatory effect). As confusion is usually the
reason for increasing the dose (is the patient not
confused because of pain?), the results are easily
predicted.
Excitatory effects are related to the synthesis of
GM1 protein. Some patients probably have multiple
gene copies for this protein. In these patients, one
can see rapid development of tolerance to opioids.
Other patients, with low or normal synthesis of
GM1, may use opioids for many years without de-
veloping tolerance.
Complexes in excitatory mode are 1000 times
more sensitive to naloxone than the inhibitory com-
plexes. This prompted some researchers to use ultra
low doses of naloxone to selectively inhibit the exci-
tatory but not inhibitory complexes. Blocking the
excitatory complexes with oseltamivir [14] has ex-
actly the same effect and improves the effectiveness
of analgesics but may also cause (transient) respira-
tory depression.
Few clinical trials have confirmed that ultra low
doses of naloxone are able to improve opioids anal-
gesia while higher doses block both inhibitory and
excitatory receptors and decrease the analgesic ef-
fect of opioids.
It is possible that in humans with an increased
capacity to synthesize GM1 protein the sensitivity to
pain is also increased. It is also possible that in the
pathogenesis of some pain syndromes, opioid-pep-
tides synthesized in the liver are playing an impor-
tant role. Their synthesis can be increased in such
conditions as hepatitis, primary biliary cirrhosis, liv-
er metastases and cholestasis. Pathologically in-
creased synthesis of endogenous opioids in the liv-
er, depending on the mix of opioids synthesized,
may be responsible for spontaneous analgesia, hy-
peralgesia and hepatogenic itch. All three condi-
tions can be reverted by naloxone. Antagonist to
opioid peptides have been discovered in the central
nervous system [15] and in that way these peptides
may modulate the sensation of pain and itch.
Despite the fact that this hypothesis is well cor-
roborated and the effects of ultra low doses of nalox-
one have been observed by many authors, this phe-
nomenon is still controversial [16, 17]. One of the
explanations of this is that different doses of nalox-
one were used in different protocols and the dose-
interval in which naloxone is active is probably very
narrow. We need more studies in order to solve
these intriguing problems.
Sensitization of the Central Nervous
System
Undoubtedly, the glutaminergic system plays an
important role in sensitization of the central ner-
vous system. Stimulation of the N-methyl-D-aspar-
tate (NMDA) receptors generates pain facilitation
which, to a large extent, escapes opioid control [18].
Stimulation of the NMDA receptors can result from
the effect of opioids but it may also be independent
of them. NMDA receptors can be stimulated by dam-
age to the central nervous system (neuropathies)
and chronic pain independent of such damage. Here,
neuropathic pain and hyperalgesia suddenly have a
common denominator and, probably, similar treat-
ment methods.
Inactive NMDA receptors are blocked by bivalent
magnesium ions. Hypomagnezemia may result in
the opening of the NMDA channels and cause pain
facilitation. In patients with hypomagnesaemia, hy-
posensitivity to opioids is frequently seen. Adminis-
tration of magnesium sulphate can restore sensitiv-
ity and result in the increased toxicity of opioids. It
should be added that longitudinal administration of
opioids by itself can lead to displacement of magne-
sium ions and to their deficiency [19].
Ketamine is a specific inhibitor of the NMDA re-
ceptors and is used to decrease development of tol-
erance to opioids when the patient needs very high
doses of opioids [20], and in some types of neuro-
pathic pain [21]. It was suggested that brief (57
days) treatment with high doses of ketamine (the so
called burst-ketamine) may lead to interruption and
reset of hyperalgesia. This kind of treatment, pro-
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viding it is well tolerated, may lead to pain reduc-
tion even for several weeks [22]. At the moment, we
do not have any evidence for this from the con-
trolled trials.
Dynorphine A
There is ample evidence that Dynorphine A of
spinal origin is responsible for the phenomenon of
opioid-induced hyperalgesia [23]. It appears that
Dynorphine A increases sensitization of the spinal
cord through the release of prostaglandins (PGE2),
which stimulate the release of neurotransmitters
(glutamate, substance P), and which are the normal
responses to electrical stimuli from the periphery [24].
Dynorphine A belongs to the family of endogenous
opioids. In painful conditions, under the influences
of opioids, it may be produced in the spinal cord, as
well as in the liver [25]. Dynorphine A is released in
the spinal cord after longitudinal administration of
opioids and in chronic pain. Increased concentrations
of pro-dynorphine, the precursor of Dynorphine A,
can also modify function of the NMDA receptors [24].
The increased activity of stimulating neuropeptides is
not a specific response to opioid administration. In-
creased activity of Vasoactive Intestinal Peptide (VIP),
Dynorphine (DYN), Cholcystokinine (CCK) and Neu-
ropeptide Y (NPY) is seen after damage to the nerves.
Again, neuropathic pain and hyperalgesia are not
very different from each other. Clinically, those two
conditions can easily be confused.
Descending control of pain impulses
The Rostral Ventromedial Medulla (RVM) con-
tains the so-called On-Off neurons which are sen-
sitive to opioids [26]. Stimulation of these neurons
can lead to facilitation of pain conveyance by the
ascending pain pathways [27]. Pain facilitation in
the spinal cord can also occur as a result of synthesis
of excitatory neuropeptides.
Not much is known about the integration of these
factors. Such studies are difficult and cumbersome.
Inhibition of all known elements at the same time
results in the reversal of hyperalgesia. However, de-
velopment of tolerance to opioids could be inhibit-
ed by the antibodies against Dynorphine A but not
after inhibition of the NMDA receptors [18]. This
suggests that the activity of Dynorphine A is related
to the development of tolerance and this mecha-
nism has an overlap with the mechanisms that lead
to a lowering of the pain threshold.
Clinical picture of hyperalgesia
It had already been noticed a long time ago that
prolonged use of analgesic opioids may result in a
decrease in their effectiveness. Doctors usually coped
with this phenomenon by increasing the opioid dose,
as long as the drugs did not cause cumbersome
adverse effects. It was thought that in cancer an
increase in nociception due to progressive disease
was the reason for the increased needs of opioids.
The fact that opioids may lower the pain threshold
was nearly never considered. The need to increase
the dose of opioids is well documented and from
time to time it may be a difficult problem, especially
in longer prognoses.
Patients who develop opioid-induced hyperalge-
sia may present with the following signs and symp-
toms. An acute, breakthrough dose of opioid may
be successful, while increasing the dose of slow re-
lease drugs or drugs administered in a syringe driver
may be ineffective or help only for a short time.
Usually, one or two days after the increase, there is
a dilemma as to whether or not to increase the dose
again. The second phenomenon is the generaliza-
tion of the pain. The primary pain symptom (pain
localization), not infrequently related to the known
localization of the tumour, may be well controlled
with opioids but the patient reports that the charac-
ter of the pain changes as the pain symptoms are
more generalized. Not infrequently, the skin is very
sensitive to pinprick and touch (hyperalgesia and
allodynia). If not specifically asked, the patient may
confuse those symptoms. The same phenomenon is
well documented after longitudinal administration
of spinal morphine [2830] and sufentanyl [31]. In
this last case, because of the specific character of
this drug, hyperalgesia occurs mainly on the lower
extremities [31].
Lowering of the pain threshold may be assessed
by the cold pressor test. A patients hand is im-
mersed in ice-cold water (0oC) and the time before
withdrawal is measured. A shortening of the time
before withdrawal may indicate a lowering of the
pain threshold. This test is performed before and
during treatment with opioids.
In the case of opioid tolerance (so-called phar-
macological tolerance), an increase in the opioid
dose leads to an increase of the analgesic effect. In
the case of pure tolerance, the character of the pain
does not change, providing there are no new ana-
tomically explainable pain localizations (for exam-
ple new bone metastases).
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Management strategy
In the case of opioid-induced hyperalgesia, the
best initial strategy is a lowering of the opioid dose.
Sometimes, it is difficult to convince the patient to
do so. Analysis of dose mistakes can be helpful.
Omission of one dose or failure to remove the fent-
anyl patch after 72 hours may have, for a while,
effects on pain which are different from expected.
Taking a detailed history from the patient is of para-
mount importance. The pain may increase or de-
crease and the patient may show symptoms of ab-
stinence. Usually, in the case of hyperalgesia, a grad-
ual decrease of the dose by 2530% may increase
the analgesic effect.
Opioid-induced hyperalgesia and opioid tolerance
should be differentiated from the intrinsic resistance
of some types of pain to opioids. Although the pain
mechanisms may overlap, some neuropathic pains
may be resistant or only partially sensitive to opioids.
In the case of such a pain, it is better to start co-
analgesics. Drugs like anticonvulsants and antidepres-
sants may be effective here. It is important, after
achieving pain control, to switch these drugs and
decrease the doses of opioid analgesics in order to
avoid or limit the development of hyperalgesia.
In case one opioid is not effective, another may
be tried. This procedure is known as opioid switch
or rotation. It looks as if opioid-induced hyperalge-
sia may develop with one but not necessarily with
other opioids. This phenomenon is known as partial
tolerance. Unfortunately, after a switch to another
opioid, analgesia may be improved but hyperalge-
sia will usually develop after some time. In one study
concerning the effectivity of an opioid switch, seven
switches were used [32]. However, a new way of
switching has recently been described. This new
method, called semi-switch, includes a decrease
in the dose of the first opioid and adding a new
opioid [30].
Buprenorphine
It looks as if opioids may differ in their ability to
provoke hyperalgesia. In a model of hyperalgesia
induced in volunteers by an electrical current, it was
shown that there are considerable differences be-
tween opioids in their ability to deal with hyperalge-
sia (antihyperalgesia effect). Fentanyl and its deriva-
tives showed potent analgesic effect in this model,
but only weak antihyperalgesic effect, while bu-
prenorphine and ketamine-S showed weaker analge-
sic effect but a potent antihyperalgetic effect [33].
Clinical data to support this observation are still miss-
ing. However, it looks as if buprenorphine may be an
interesting drug in the case of endogenous hyperopi-
oidaemia, where the synthesis of endogenous opio-
ids (in the liver) is increased. These phenomena are
known to induce itch of cholestasis [34]. There are
suggestions that a damaged liver (as a result of
cholestasis, liver metastasis and others) is able to
produce high amounts of endogenous opioids. These
opioids, probably depending on their mix, may pre-
cipitate itch, hyperalgesia or hypoalgesia [35].
Buprenorphine, with its high affinity for the opi-
oid receptor but only a weak stimulation (efficacy),
may act like an antagonist, similar to naloxone in
blocking access to the opioid receptors for endoge-
nous opioids. This kind of effect helps to under-
stand why buprenorphine may be effective in the
treatment of hepatogenic itch [36]. It is possible
that the antihyperalgesic effect of buprenorphine is
an important element in its unusual analgesic prop-
erties. The recent introduction of a new formulation
of buprenorphine in patches will certainly boost in-
terest in these effects. We may soon expect new and
interesting data from clinical trials. Until now, the
feared ceiling effect of buprenorphine has not been
shown in humans [37].
Ketamine
In the case of pains resistant to opioids, ket-
amine may offer an interesting additional effect [38].
Despite positive results in the treatment of cancer
pain, systematic analysis could not (so far) establish
equivocal conclusions [20]. Ketamine can be used
orally together with morphine or other opioids [39].
Sometimes ketamine needs to be administered
parenterally, usually in a subcutaneous syringe driv-
er [40]. Recently published data on burst-ketamine
protocols have been exceptionally interesting. Ket-
amine is used in relatively high doses for several
days. After discontinuation of treatment, the anal-
gesic effect persists for several weeks [22].
Magnesium sulphate
Another strategy to deal with the problem of
hyperalgesia is the administration of magnesium
sulphate, especially where magnesium deficiency can
be present as in patients treated in the past with cis-
-platin. These patients may have damaged renal tu-
bules and may not reabsorb magnesium from urine.
In addition, a rapid growth of tumour mass may
lead to increased magnesium losses. Another risk
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factor is chronic diarrhoea or a short bowel syn-
drome due to, for example, an ileostomy. All these
conditions may lead to hypomagnesaemia. Unfor-
tunately, magnesium is poorly absorbed from the
gastrointestinal tract and the preferred way for its
administration is intravenous infusion [41]. Doses of
several grams of magnesium sulphate per day are
not infrequent. Administration in one intravenous
shot is not advisable and may be dangerous. After
parenteral administration and equilibration, mag-
nesium can be administered orally in the form of
magnesium hydroxide, usually in combination with
calcium gluconate. Plasma magnesium concentra-
tions are not representative for magnesium stores
because most magnesium is found intracellularly
and not in plasma. Excretion of magnesium ions
from the cells may increase plasma levels while the
cells themselves may be depleted of this ion. In con-
trast, low plasma magnesium invariably shows a
magnesium shortage. More reliable is the magne-
sium retention test [42]. A patient receives a certain
dose of magnesium sulphate intravenously and its
excretion in the urine is measured. It is believed that
magnesium retention correlates to magnesium de-
ficiency. Even patients who eat well may develop
magnesium deficiency in different pathological states
as well as with stress. Magnesium in our diet has
decreased by half in the last 100 years. Many drugs
which were used frequently in the past, and which
contained magnesium ions (laxatives and antacids),
are not in use any more.
Ultra low doses of opioid antagonists
The hypothesis that ultra low doses of naloxone
are able to improve quality of opioid analgesia and
diminish at least some adverse effects of opioids is
very interesting. The dose interval in which nalox-
one would be able to have this effect is probably
very narrow and possibly different in different indi-
viduals. This is probably the reason why this method
has not been investigated widely and why the exist-
ing clinical data are contradictory [16, 17]. From
personal experience, we can say that naloxone can
be useful in different clinical situations. We have
tried using naloxone in more than 40 patients with,
we must say, mixed results. Most of the patients
used naloxone as the last resort treatment when
their pain was unrelieved and the patient was re-
ceiving very high doses of opioids. It is important to
state that all patients started with 3 mcg/kg/24 hours.
The results, if any, were seen within several hours
after beginning the infusion. In several patients, apart
from better control of the pain, we observed (slight)
respiratory depression. A decrease in the excitatory
effect on the respiratory centre is one of the most
interesting effects of naloxone, objectively confirm-
ing the hypothesis of inverted opioid receptors. It
is now obvious that naloxone does not solve many
problems but instead creates a new one. After sev-
eral days of treatment, the patient experiences local
irritation and inflammation at the infusion site in
the case of subcutaneous administration. Naloxone
cannot be administered orally as its oral bioavail-
ability is not higher than 13%. In several cases treat-
ed by us in the Netherlands it was possible to ad-
minister a water solution of naltrexone which was
prepared after dissolution of the tablet. We do not
know the shelf life of such a solution and further
research is hampered because of this. Several peo-
ple treated with oral naltrexone (once daily 15 mcg/
24 hours) benefited greatly from this treatment. One
patient with a non-malignant pain has already been
treated with naltrexone for 5 years. We still hope
that this drug will be investigated formally as an
adjuvant analgesic.
Clonidine
Clonidine is an alpha-2 agonist adrenergic drug,
which has been used for a long time in the treat-
ment of arterial hypertension. As well as its blood
pressure lowering effects, clonidine is used in the
treatment of symptoms of opioid abstinence [43].
As has already been stated, opioids may not only
induce analgesia but also hyperalgesia. After sud-
den discontinuation of opioids, patients, among oth-
er abstinence symptoms, may experience the severe
pain of hyperalgesia. This hyperalgesia may be sen-
sitive to clonidine. Clonidine is frequently used spi-
nally, together with morphine [4447]. Clonidine
can be used in subcutaneous infusions as an adju-
vant treatment when the patient develops a rapid
tolerance to opioids. We do not have much clinical
experience with this drug. However, further studies
are certainly worthwhile. It is important that candi-
dates for this treatment have at least normal blood
pressure and that this parameter is monitored dur-
ing treatment.
Conclusions
Administration of opioids to relieve pain may
also cause hyperalgesia. This second phenomenon
is only seen in some patients but it may explain the
development of tolerance, addiction to opioids and
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pain insensitivity to opioids. There are several differ-
ent strategies for dealing with hyperalgesia. One of
the basic principles is obtaining normal body magne-
sium stores. This can be done by the intravenous
infusion of magnesium sulphate. If magnesium sul-
phate infusion is ineffective, one can use ketamine or
ultra low doses of opioid antagonists. The most ef-
fective strategy, however, is lowering the dose of
opioids. Very promising is the use of partial agonists
like buprenorphine in patches. Buprenorphine seems
to be one of the few opioids which do not produce
hyperalgesia. We certainly need more studies on this.
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